United States regulators have officially accept the first pill that contains a digital tracking sensor to alert doctors and caregivers as to whether a patient is taking a medication as prescribed.
The tablet is created for sick people with schizophrenia, bipolar disorder and depression, As stated by the US Food and Drug Administration. And the pill is called Abilify MyCite (aripiprazole tablets with sensor),
When a patient takes the pill, and a sensor inside the pill activates when it reaches the stomach fluids, sending a message to a wearable patch.
This patch then transfer the message to a mobile application, so that a doctor and up to four caregivers, friends or family members can see the information via a web-based portal.
Mitchell Mathis, director of the division of psychiatry products in the FDA’s Center for Drug Evaluation and Research, said that “Being able to track intake of medications authorized for mental illness may be helpful for some patients”.
The FDA aids the growth and use of new technology in prescription drugs and is devoted to working with companies to comprehend how technology might interest patients and prescribers.
The manufacturer of Abilify, Japan-based Otsuka Pharmaceutical, said it is not clear whether the tracking device will actually help improve patients’ ability to take their medication daily as instructed despite the fact that the sensor can alert caregiver.
Read also: Mesothelioma: You Need A Viable Law Firm
The FDA accept Abilify in 2002 to treat schizophrenia, which affects about one per cent of the US population.
The ingestible sensor used in Abilify MyCite was first permit on the market by the FDA in 2012.
Proteus Digital Health create the sensor technology and patch, and are approved for use with the current medications in the United States and Europe.
Some specialist asked questions about the choice of Abilify as the drug in which to test the sensor.
Victim with a tendency in persecution direction may feel a bit uncomfortable being observed in this fashion,” said Seth Mandel, chairman of psychiatry at Northwell Health’s Huntington Hospital in New York.
“Patients with bipolar disorder and schizophrenia are very often non-compliant with their medication and the result is almost always deteriorate,” he added.
“Generally, this seems to potentially be a vital process in our never-ending fight to improve patient commitment to psychotropic medication.”